



## Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results

March 19, 2019

CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report fourth quarter and full-year 2018 financial results on Thursday, March 28, 2019, before market open.

The company will not be conducting a teleconference in conjunction with its financial results press release.

### About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit [www.rubiustx.com](http://www.rubiustx.com), or follow us on [Twitter](#) and [LinkedIn](#).

### Contact:

Lori Melançon  
Vice President, Corporate Communications and Investor Relations  
+1 (617) 949-5296  
[lori.melancon@rubiustx.com](mailto:lori.melancon@rubiustx.com)

### Media Contact:

Dan Budwick  
1AB.  
+1 (973) 271-6085  
[dan@1abmedia.com](mailto:dan@1abmedia.com)



Source: Rubius Therapeutics